Oneness Biotech Co., Ltd. receives a Japanese patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.

Published Date:2023-12-04

Statement
No	1	Date of announcement	2023/12/04	Time of announcement	18:55:48
Subject	Oneness Biotech Co., Ltd. receives a Japanese patent titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” on FB825.
To which item it meets	paragraph 53			Date of events	2023/12/04
Date of occurrence of the event:2023/12/04 Company name:ONENESS BIOTECH CO., LTD. Relationship to the Company (please enter “head office” or “subsidiaries”):head office Reciprocal shareholding ratios:NA Cause of occurrence:The Company has received humanized Anti-CεmX monoclonal antibody (FB825) Japanese patent certificate from the patent agency. The patent is titled “TREATING IGE-MEDIATED ALLERGIC DISEASES” under the patent number 7286665. Countermeasures:None Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): This patent expanded our patent protection to cover indications related to IgE-mediated allergic diseases as well as long-acting treatment regimen. This patent strategy will create barriers to entry and enhance the opportunities for maximizing patent protection for FB825. In addition to Russian, the patent applications have been filed in the countries or regions with large healthcare spending. The patent protection can be extended until 2038.